More than 50% of men now face erectile dysfunction after the age of 40. In a few cases, men in…
BEIJING, April 27, 2025 (GLOBE NEWSWIRE) -- On April 25, 2025, the 66th (Spring 2025) National Pharmaceutical Machinery Exposition &…
After six months of research on the ingredients and thousands of feedback from real consumers, we can safely say that…
Data Presented at the AUA Meeting Reflect Longest-Term Data among FIT InterventionsSOUTH SAN FRANCISCO, Calif., April 26, 2025 (GLOBE NEWSWIRE)…
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3%…
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf…
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder…
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of…
Saint Herblain (France), April 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced…
TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates…